CN102333762B - 乙胺类化合物及其在治疗抑郁症中的用途 - Google Patents

乙胺类化合物及其在治疗抑郁症中的用途 Download PDF

Info

Publication number
CN102333762B
CN102333762B CN200980157411.9A CN200980157411A CN102333762B CN 102333762 B CN102333762 B CN 102333762B CN 200980157411 A CN200980157411 A CN 200980157411A CN 102333762 B CN102333762 B CN 102333762B
Authority
CN
China
Prior art keywords
compound
amine
acid
methyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980157411.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102333762A (zh
Inventor
M.巴勒斯特拉
P.伯恩斯坦
G.E.厄恩斯特
W.弗里茨
J.P.麦克考利
D.奴吉尔
L.沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102333762(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN102333762A publication Critical patent/CN102333762A/zh
Application granted granted Critical
Publication of CN102333762B publication Critical patent/CN102333762B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
CN200980157411.9A 2008-12-24 2009-12-22 乙胺类化合物及其在治疗抑郁症中的用途 Expired - Fee Related CN102333762B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24
US61/140,673 2008-12-24
PCT/SE2009/051493 WO2010074647A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Publications (2)

Publication Number Publication Date
CN102333762A CN102333762A (zh) 2012-01-25
CN102333762B true CN102333762B (zh) 2014-06-11

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980157411.9A Expired - Fee Related CN102333762B (zh) 2008-12-24 2009-12-22 乙胺类化合物及其在治疗抑郁症中的用途

Country Status (31)

Country Link
US (4) US8013165B2 (enExample)
EP (2) EP2391606A4 (enExample)
JP (1) JP5491524B2 (enExample)
KR (1) KR20110097996A (enExample)
CN (1) CN102333762B (enExample)
AR (1) AR074981A1 (enExample)
AU (1) AU2009330745B2 (enExample)
BR (1) BRPI0923476A2 (enExample)
CA (1) CA2748235A1 (enExample)
CL (1) CL2011001590A1 (enExample)
CO (1) CO6450688A2 (enExample)
CR (1) CR20110365A (enExample)
CU (1) CU24017B1 (enExample)
DO (1) DOP2011000205A (enExample)
EA (1) EA201190064A1 (enExample)
EC (1) ECSP11011161A (enExample)
GT (1) GT201100186A (enExample)
HN (1) HN2011001773A (enExample)
IL (1) IL213518A0 (enExample)
MX (1) MX2011006680A (enExample)
NI (1) NI201100131A (enExample)
NZ (1) NZ593282A (enExample)
PE (1) PE20120249A1 (enExample)
SA (1) SA109310013B1 (enExample)
SG (2) SG171928A1 (enExample)
SV (1) SV2011003962A (enExample)
TW (1) TWI442922B (enExample)
UA (1) UA106056C2 (enExample)
UY (1) UY32360A (enExample)
WO (1) WO2010074647A1 (enExample)
ZA (1) ZA201105441B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110097996A (ko) * 2008-12-24 2011-08-31 아스트라제네카 아베 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540318A1 (en) * 1991-10-30 1993-05-05 Fisons Corporation 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
WO1993020052A1 (en) * 1992-04-03 1993-10-14 Fisons Corporation Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
WO2000056324A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab The use of certain affinity nmda antagonists as antidepressants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (enExample) 1973-05-26 1982-11-30
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
ES2083972T3 (es) 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
DK0898566T3 (da) * 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
KR20110097996A (ko) 2008-12-24 2011-08-31 아스트라제네카 아베 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540318A1 (en) * 1991-10-30 1993-05-05 Fisons Corporation 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
WO1993020052A1 (en) * 1992-04-03 1993-10-14 Fisons Corporation Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
WO2000056324A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab The use of certain affinity nmda antagonists as antidepressants

Also Published As

Publication number Publication date
CA2748235A1 (en) 2010-07-01
US8013165B2 (en) 2011-09-06
EP2391606A1 (en) 2011-12-07
CU20110141A7 (es) 2012-01-31
US20120277272A1 (en) 2012-11-01
EP2610246A1 (en) 2013-07-03
EA201190064A1 (ru) 2012-02-28
CR20110365A (es) 2011-08-09
ECSP11011161A (es) 2011-07-29
GT201100186A (es) 2013-10-08
ZA201105441B (en) 2012-03-28
CU24017B1 (es) 2014-07-30
SG171928A1 (en) 2011-07-28
US20130137731A1 (en) 2013-05-30
EP2391606A4 (en) 2012-06-13
PE20120249A1 (es) 2012-04-19
SV2011003962A (es) 2012-01-06
CL2011001590A1 (es) 2012-06-22
DOP2011000205A (es) 2011-07-15
SA109310013B1 (ar) 2013-07-28
NZ593282A (en) 2013-06-28
BRPI0923476A2 (pt) 2016-01-19
JP5491524B2 (ja) 2014-05-14
US9035065B2 (en) 2015-05-19
AU2009330745B2 (en) 2012-04-05
NI201100131A (es) 2012-03-19
IL213518A0 (en) 2011-07-31
JP2012513993A (ja) 2012-06-21
MX2011006680A (es) 2011-07-12
AR074981A1 (es) 2011-03-02
WO2010074647A1 (en) 2010-07-01
CN102333762A (zh) 2012-01-25
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
TWI442922B (zh) 2014-07-01
HN2011001773A (es) 2014-08-18
TW201028149A (en) 2010-08-01
UY32360A (es) 2010-07-30
AU2009330745A1 (en) 2011-08-04
CO6450688A2 (es) 2012-05-31
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
KR20110097996A (ko) 2011-08-31

Similar Documents

Publication Publication Date Title
JP5474153B2 (ja) Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体
US20100184738A1 (en) Uses of cinnoline compounds to treat schizophrenia
TW200826939A (en) N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide
TW201938159A (zh) Keap1之btb域之小分子調節劑
TWI442922B (zh) 乙胺化合物及其使用方法
EP2254876A1 (en) Compound (r) -n*6*-ethyl-6, 7-dihydro-5h-indeno (5, 6- d) thiazole-2, 6-diamine and the use as antipsychotics
JP2920727B2 (ja) 新規１，４−（ジフェニルアルキル）ホモピペラジン誘導体
HK1186188A (en) Ethanamine compounds and methods of using the same
EP3010900B1 (en) 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
JP2956788B2 (ja) スピロイソインドリン化合物、その製造方法、それを含有する神経症を治療するための医薬およびそれを製造するための中間体
AU2012203913A1 (en) Ethanamine compounds and their use for treating depression
CN101544604B (zh) 一种三环化合物
JP2004511487A (ja) ピロール−縮合モルフィノイド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140611

Termination date: 20161222